ResearchRSSToday
A new study found that babies born early who develop a lung condition called bronchopulmonary dysplasia (BPD) often need medications to treat high blood pressure in their lungs (pulmonary hypertension). However, as these children grow into toddlers around age 2, many of them stop needing these medications. This suggests that the lung condition may improve naturally as kids get older.
WHY IT MATTERSIf your child with BPD and pulmonary hypertension is on PH medications, this research suggests their doctor may be able to reduce or stop treatment as they grow, potentially reducing long-term medication burden and side effects.
ResearchRSS2 days ago
Scientists found that a gene called RUNX1 might help doctors predict when patients with pulmonary arterial hypertension (PAH) — a serious lung disease that makes it hard to pump blood — could develop heart problems. When the right side of the heart weakens in PAH patients, it becomes very dangerous. This discovery could help doctors catch and treat these heart problems earlier.
WHY IT MATTERSIf RUNX1 becomes a validated biomarker, PAH patients could receive earlier interventions to prevent right heart failure, potentially improving survival and quality of life before irreversible damage occurs.
NewsRSS2 days ago
This article is a quiz about nerandomilast, a medicine being studied to treat progressive pulmonary fibrosis (PPF), which is a lung disease where lung tissue becomes scarred and stiff over time, making it harder to breathe. The quiz helps patients and caregivers learn more about this potential treatment option. It's a way to test your understanding of how this medicine might help people with this serious lung condition.
WHY IT MATTERSPatients with progressive pulmonary fibrosis have limited treatment options, so learning about emerging therapies like nerandomilast helps them stay informed about potential new ways to slow lung damage.
AdvocacyRSS2 days ago
People with pulmonary hypertension (PH) often feel pressure to push through exhaustion and symptoms like chest pain, but this approach can actually make their condition worse. The article explains that rest and pacing activities is important for managing PH, rather than trying to power through difficult days. Ignoring your body's signals can lead to more frustration and health problems.
WHY IT MATTERSThis article addresses a critical but often overlooked aspect of PH management: understanding that rest is medical treatment, not laziness, which can help patients make better decisions about activity and reduce unnecessary symptom flare-ups.
NewsRSS2 days ago
This article is a quiz that tests what you know about riociguat, a medication used to treat pulmonary arterial hypertension (PAH). PAH is a rare condition where blood vessels in the lungs become narrowed, making it harder for the heart to pump blood through them. The quiz helps patients and caregivers learn more about how this treatment works.
WHY IT MATTERSUnderstanding how riociguat works and its role in PAH treatment can help patients make informed decisions about their care and have more meaningful conversations with their doctors about their treatment options.
NewsRSS3 days ago
A person with pulmonary hypertension shares how their life has changed as their health improved. When they were first diagnosed, just surviving day-to-day was the biggest challenge. Now that their condition is more stable, they're learning how to enjoy life and do the things they want to do, rather than just focusing on staying alive.
WHY IT MATTERSThis patient perspective shows that pulmonary hypertension care extends beyond medical treatment—people need support learning how to rebuild their lives and set new goals after stabilizing their condition.
Clinical trialRSS3 days ago
A new clinical trial has started testing a drug called IKT-001 in people with pulmonary arterial hypertension (PAH), a rare condition where blood vessels in the lungs become narrowed and make it hard for the heart to pump blood. This is a large Phase 3 trial, which is a late-stage test that happens before a drug might be approved. Nearly 500 adults will participate to see if this drug works better than current treatments.
WHY IT MATTERSIf you have PAH and are already on stable treatment, you may be eligible to join the IMPROVE-PAH trial and potentially access IKT-001 before it becomes widely available.
ResearchRSS3 days ago
A new study used wrist sensors to track physical activity in children with pulmonary hypertension (a condition where blood pressure in the lungs is too high). Researchers found that kids with this condition exercise less intensely and for shorter periods than healthy children. Children with more severe cases had even bigger drops in exercise intensity.
WHY IT MATTERSUnderstanding how pulmonary hypertension limits children's physical activity can help doctors and families set realistic exercise goals and monitor whether treatments are helping kids stay more active.
AdvocacyRSS3 days ago
This article uses the excitement of NASA's Artemis II space mission as inspiration to encourage big dreams about finding a cure for pulmonary hypertension, a serious lung disease that affects blood vessels. The author draws a parallel between humanity's ability to reach for the stars and the hope that patients with pulmonary hypertension should have for breakthrough treatments. The piece is motivational rather than reporting on specific medical news or research developments.
WHY IT MATTERSThis article may resonate emotionally with pulmonary hypertension patients by framing their disease journey within a larger narrative of human achievement and possibility, though it does not announce any new treatments, trials, or clinical developments.
NewsRSS3 days ago
Orenitram is a pill form of a medicine called treprostinil that helps people with pulmonary arterial hypertension (a serious lung condition where blood vessels in the lungs become too narrow). You take it by mouth 2-3 times a day with food. This medicine helps patients exercise better and slows down how fast their disease gets worse.
WHY IT MATTERSThis oral option gives PAH patients an alternative to injected or inhaled treprostinil, making treatment more convenient for daily management.
ResearchRSS3 days ago
A study from Japan found that people with pulmonary hypertension (a condition where blood vessels in the lungs become stiff and narrow) who have higher pulmonary vascular resistance—a measure of how hard the heart has to work to pump blood through the lungs—tend to have worse health outcomes. The study also looked at whether a type of diabetes medication called SGLT2 inhibitors might help these patients.
WHY IT MATTERSIf you have pulmonary hypertension related to heart disease, knowing that high pulmonary vascular resistance predicts worse outcomes could help your doctor decide whether to start more aggressive treatment earlier or monitor you more closely.
ResearchRSS3 days ago
Researchers found that data from smartphones and wearable devices, collected over several years through a health app, can help doctors identify people with a rare lung disease called idiopathic pulmonary arterial hypertension (IPAH) earlier than before. The study used information like heart rate and activity levels from the My Heart Counts app to spot differences between people with IPAH and healthy people. This discovery could lead to faster diagnosis of this serious condition.
WHY IT MATTERSEarlier detection of IPAH could allow patients to start treatment sooner, potentially slowing disease progression and improving outcomes for this condition that currently has no cure.
NewsRSS3 days ago
A person with pulmonary hypertension (PH), a rare lung disease that makes it hard for the heart to pump blood through the lungs, shares what it was like growing up with this condition. They had to frequently miss school and explain their illness to classmates who asked questions about their absences. This article highlights the social and emotional challenges that young people with chronic rare diseases face alongside their medical treatment.
WHY IT MATTERSPatients with pulmonary hypertension and their families can find validation and community in peer experiences, while healthcare providers gain insight into the psychosocial impact of PH that extends beyond physical symptoms.
Clinical trialRSS3 days ago
A company called Allrock Bio is testing a new oral medication called ROC-101 for pulmonary hypertension (a condition where blood pressure in the lungs becomes dangerously high). This is a Phase 2a trial, which means they're checking if the drug is safe and works well as an add-on treatment. The trial is now enrolling patients across the U.S., Canada, and Europe.
WHY IT MATTERSIf ROC-101 proves effective as an add-on therapy, it could offer pulmonary hypertension patients a new oral option to combine with their existing treatments, potentially improving symptom control.
AdvocacyRSS3 days ago
A mother shares her personal story about being diagnosed with pulmonary hypertension three months after giving birth to her second son in 2023. The article focuses on how she manages her condition while raising three boys and the emotional impact this serious lung disease has had on her life and family.
WHY IT MATTERSPatient stories about pulmonary hypertension help newly diagnosed patients and families understand that others are managing this serious condition while maintaining family life, which can provide hope and practical insights into daily living with the disease.
ResearchBIORXIVApr 5
Researchers studied the genes of people with pulmonary fibrosis (a disease where lung tissue becomes scarred and stiff) to find rare genetic changes that might cause the disease. They found that problems in genes related to how cells maintain their structure may play an important role in developing pulmonary fibrosis. This discovery could help doctors better understand why some people develop this serious lung condition.
WHY IT MATTERSIf you or a family member has pulmonary fibrosis, this research could eventually help explain your genetic risk and lead to new treatments targeting the cellular structures that are damaged in this disease.
Clinical trialUNITERAREApr 3
Researchers at the University of Alabama at Birmingham are looking for premature babies to join a study about pulmonary hypertension—a condition where blood pressure in the lungs gets too high. The study will test different oxygen level targets to see which approach helps prevent or reduce lung problems in preterm infants. This trial is now actively recruiting participants and is expected to start in April 2026.
WHY IT MATTERSThis trial directly addresses a common complication in premature infants where improper oxygen management can cause lasting lung damage, making oxygen saturation targeting strategies critical for improving long-term outcomes in this vulnerable population.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for idiopathic pulmonary fibrosis (a lung disease where lung tissue becomes scarred and stiff over time) is currently closed and is not accepting new applications. This program previously offered up to $12,000 per year to help patients pay for treatment costs. The fund status changed on April 2, 2026.
WHY IT MATTERSIf you have idiopathic pulmonary fibrosis and need help paying for medications or treatment, you cannot currently apply to this specific PAN Foundation program, so you'll need to explore other financial assistance options.
ResearchPUBMEDMar 26
Doctors who treat children with rare lung diseases in German-speaking countries were surveyed about their experience and confidence in diagnosing and treating these conditions. The study found that while common rare lung diseases like cystic fibrosis have good support systems, many other rare lung diseases don't have clear treatment guidelines. Researchers want to understand what training and resources doctors need to better help children with these uncommon lung problems.
WHY IT MATTERSIf you have a child with a rare lung disease, this research could lead to better training for pediatric lung doctors in your region, potentially reducing diagnostic delays and improving access to specialized care.
ResearchPUBMEDMar 26
Doctors found a rare lung disease called pulmonary light chain deposition disease (PLCDD) that creates cysts and bumps in the lungs. This disease is hard to diagnose because it looks similar to other lung conditions, but special imaging scans and blood tests for abnormal proteins can help identify it. The article explains how doctors should think about this disease when patients have unusual cyst patterns in their lungs.
WHY IT MATTERSIf you have been diagnosed with an unusual cystic lung disease that doesn't fit typical patterns, your doctor should consider testing for light chain deposition disease, which requires specific blood work and imaging to confirm.